Drug Database
Back to search

Belgium· BE-AMP-SAM205247-00

Aggrastat 0.25 mg/ml

A tirofiban product containing tirofiban hydrochloride, registered in Belgium by Advanz Pharma. The same ATC class is registered in 11 of our 19 countries.

ATC B01AC17

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedAggrastat 0.25 mg/mlATCB01AC17REGISTER NO.BE-AMP-SAM205247-00PACKS LISTED2CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about tirofiban hydrochlorideAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Tirofiban is registered in 11 of 19 countries.

Countries holding a registration under ATC B01AC17 (tirofiban), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 7 of them publish a price we can compare per daily dose
Search tirofiban products by name

Tirofiban · ATC B01AC17

11 / 19 countries

  • Belgiumprice
  • Canada
  • Finlandprice
  • Franceprice
  • Germany
  • Netherlands
  • Norwayprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Tirofiban Hydrochloride
Manufacturer
Advanz Pharma
Country
Belgium (BE)
ATC code
B01AC17
ATC class
Tirofiban
Defined daily dose
10 mg, P
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

  • be_apb
    0768002
  • be_apb
    1506088

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

159 interactions on record for tirofiban.

Graded by severity as the source publishes them — 62 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check tirofiban against other medicinesHow interaction checks work

Tirofiban · interactions on record

159 records

  • 62 severe
  • 75 moderate
  • 22 info

Most severe, free to view

  • DicoumarolB01AA01severe
  • WarfarinB01AA03severe
  • HeparinB01AB01severe
  • DalteparinB01AB04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Tirofiban in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All tirofiban products

Authorised across Europe · EMA

The same active substance is authorised in 19 EEA countries. Names it is sold under:

  • Austria · Aggrastat
  • Bulgaria · Аграстат, Тирофибан Чайкафарма
  • Cyprus · Aggrastat, Αggrafiban
  • Germany · Aggrastat, Tirofiban Ibisqus
  • Estonia · Aggrastat
  • Spain · Agrastat, Tirofiban Altan Pharmaceuticals S.A.
  • Finland · Aggrastat
  • France · Agrastat, Tirofiban Altan
  • United Kingdom (Northern Ireland) · Aggrastat, Tirofiban Eugia (Uk)
  • Greece · Aggrastat, Αggrafiban
  • Hungary · Aggrastat
  • Italy · Aggrastat, Tirofiban Aurobindo
  • Lithuania · Aggrastat
  • Luxembourg · Aggrastat
  • Latvia · Aggrastat
  • Malta · Aggrastat, Tirofiban Ibigen
  • Netherlands · Aggrastat, Tirofiban Eugia
  • Portugal · Tirofibano, Tirofibano Generis
  • Sweden · Aggrastat

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/14d78e0e-c91e-412c-84af-395c0894366e
GET /v1/drugs/14d78e0e-c91e-412c-84af-395c0894366e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Concentrate for solution for infusion",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Aggrastat 0.25 mg/ml",
  "name_fr": "Aggrastat 0.25 mg/ml",
  "name_nl": "Aggrastat 0.25 mg/ml",
  "amp_code": "SAM205247-00",
  "strengths": [
    "281.0000",
    "281.0000",
    "250.0000",
    "250.0000",
    "8.0000"
  ],
  "pack_count": 1,
  "substances": [
    "Tirofiban Hydrochloride",
    "Tirofiban",
    "Sodium Chloride",
    "Sodium Hydroxide"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Tirofiban",
  "authorisation_numbers": [
    "BE205247"
  ]
}
API referenceMCP serverPlans

See everything about tirofiban.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console